Pharmacoenhancement of protease inhibitors.
Toxicity, adherence problems, and virological failure may limit treatment by protease inhibitor-containing regimens at standard doses. Addition of low-dose ritonavir results in a high plasma concentration of coadministered protease inhibitor resulting in decreased pill burden, a reduction in the number of doses, fewer food and/or fluid restrictions, and a higher rate of virological suppression. These effects are due to improved pharmacokinetics of coadministered protease inhibitors.
Motwani
Bharat
B
Division of Infectious Diseases, Department of Internal Medicine, FUHS/The Chicago Medical School, Chicago, Illinois 60064, USA.
Khayr
Walid
W
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors; D000818:Animals; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D065607:Cytochrome P-450 Enzyme Inhibitors; D017320:HIV Protease Inhibitors; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir